These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 1168690)

  • 41. Enhanced reactive lysis of paroxysmal nocturnal hemoglobinuria erythrocytes by C5b-9 does not involve increased C7 binding or cell-bound C3b.
    Rosenfeld SI; Jenkins DE; Leddy JP
    J Immunol; 1985 Jan; 134(1):506-11. PubMed ID: 3964820
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antigenic relationship between the fourth component of human and guinea pig complement.
    Ohanian SH; Borsos T
    J Immunol; 1975 Jan; 114(1 Pt 1):161-4. PubMed ID: 46239
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Activation of the complement attack mechanism in the fluid phase and its control by C567-INH: lysis of normal erythrocytes initiated by zymosan, endotoxin, and immune complexes.
    Lint TF; Behrends CL; Baker PJ; Gewurz H
    J Immunol; 1976 Nov; 117(5 Pt 1):1440-6. PubMed ID: 1002985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The interaction of Escherichia coli with normal human serum: the kinetics of serum-mediated lipopolysaccharide release and its dissociation from bacterial killing.
    Tesh VL; Duncan RL; Morrison DC
    J Immunol; 1986 Aug; 137(4):1329-35. PubMed ID: 3525676
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Sublytic complement attack protects tumor cells from lytic doses of antibody and complement.
    Reiter Y; Ciobotariu A; Fishelson Z
    Eur J Immunol; 1992 May; 22(5):1207-13. PubMed ID: 1577063
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Antibody and complement modulation of tumor cell growth in vitro and in vivo.
    Shearer WT; Parker CW
    Fed Proc; 1978 Aug; 37(10):2385-9. PubMed ID: 354972
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antibody-mediated complement activation on nucleated cells. A quantitative analysis of the individual reaction steps.
    Ollert MW; Kadlec JV; David K; Petrella EC; Bredehorst R; Vogel CW
    J Immunol; 1994 Sep; 153(5):2213-21. PubMed ID: 8051421
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The reaction of zymosan with the properdin system in normal and C4-deficienct guinea pig serum. Demonstration of C3- and C5-cleaving multi-unit enzymes, both containing factor B, and acceleration of their formation by the classical complement pathway.
    Brade V; Lee GD; Nicholson A; Shin HS; Mayer MM
    J Immunol; 1973 Nov; 111(5):1389-400. PubMed ID: 4795621
    [No Abstract]   [Full Text] [Related]  

  • 49. The effect of antibodies to complement components C2, C3 and C5 on the production and action of lymphotoxin.
    Gately MK; Mayer MM
    J Immunol; 1972 Oct; 109(4):728-34. PubMed ID: 5074329
    [No Abstract]   [Full Text] [Related]  

  • 50. Isolation of C4-binding protein from guinea pig plasma and demonstration of its function as a control protein of the classical complement pathway C3 convertase.
    Burge J; Nicholson-Weller A; Austen KF
    J Immunol; 1981 Jan; 126(1):232-5. PubMed ID: 6778916
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of antibody-complement-mediated killing of tumor cells by hormones.
    Schlager SI; Ohanian SH; Borsos T
    Cancer Res; 1976 Oct; 36(10):3672-7. PubMed ID: 182362
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of complement-dependent antibody-mediated lysis of target cells acutely infected with measles.
    Hicks JT; Klutch MJ; Albrecht P; Frank MM
    J Immunol; 1976 Jul; 117(1):208-15. PubMed ID: 819582
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
    Kievits F; Kijlstra A
    Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cholesterol-dependent human complement activation resulting in damage to liposomal model membranes.
    Alving CR; Richards RL; Guirguis AA
    J Immunol; 1977 Jan; 118(1):342-7. PubMed ID: 830757
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the effect of various antisera and cobra venom factor on inflammatory reactions in guinea-pig skin. I. Non-specific inflammation due to the intradermal injection of turpentine.
    Lewis E; Turk JL
    J Pathol; 1975 Feb; 115(2):97-109. PubMed ID: 1080193
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Interactions of chrysotile asbestos fibres with the complement system.
    Saint-Remy JM; Cole P
    Immunology; 1980 Oct; 41(2):431-7. PubMed ID: 6904360
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A complement-resistant HeLa cell line (T638) is blocked at the step of C3 deposition.
    Santi P; Joiner KA; Hammer CH; Frank MM; Tosi R
    J Immunol; 1987 May; 138(10):3385-91. PubMed ID: 2952716
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Classical pathway of complement activation in mammalian kidneys.
    Zwirner J; Felber E; Burger R; Bitter-Suermann D; Riethmüller G; Feucht HE
    Immunology; 1993 Oct; 80(2):162-7. PubMed ID: 8262545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The third component of complement (C3) bound to tumor target cells enhances their sensitivity to killing by activated macrophages.
    Bara S; Lint TF
    J Immunol; 1987 Feb; 138(4):1303-9. PubMed ID: 3100634
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Homozygous human C3 deficiency. The role of C3 in antibody production, C-1s-induced vasopermeability, and cobra venom-induced passive hemolysis.
    Alper CA; Colten HR; Gear JS; Rabson AR; Rosen FS
    J Clin Invest; 1976 Jan; 57(1):222-9. PubMed ID: 1107355
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.